Patents by Inventor Mincheng Zhang

Mincheng Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TLR7 agonist for treating colorectal cancer and pharmaceutical combination thereof
    Patent number: 12195468
    Abstract: Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.
    Type: Grant
    Filed: October 12, 2019
    Date of Patent: January 14, 2025
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Hongjiang Xu, Mincheng Zhang, Ying Zhang, Wei Song, Ling Yang, Xiquan Zhang
  • TLR7 agonist and pharmaceutical combination thereof for treating lung cancer
    Patent number: 12128047
    Abstract: The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: October 29, 2024
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xiquan Zhang, Ling Yang, Ying Zhang, Mincheng Zhang, Wei Song, Hongjiang Xu
  • TLR7 AGONIST FOR TREATING COLORECTAL CANCER AND PHARMACEUTICAL COMBINATION THEREOF
    Publication number: 20220235053
    Abstract: Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.
    Type: Application
    Filed: October 12, 2019
    Publication date: July 28, 2022
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Hongjiang XU, Mincheng ZHANG, Ying ZHANG, Wei SONG, Ling WANG, Xiquan ZHANG
  • TLR7 AGONIST AND PHARMACEUTICAL COMBINATION THEREOF FOR TREATING LUNG CANCER
    Publication number: 20210220362
    Abstract: The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer.
    Type: Application
    Filed: May 24, 2019
    Publication date: July 22, 2021
    Inventors: Xiquan Zhang, Ling Yang, Ying Zhang, Mincheng Zhang, Wei Song, Hongjiang Xu